Pulmonx Corp (LUNG) - Total Liabilities
Based on the latest financial reports, Pulmonx Corp (LUNG) has total liabilities worth $74.20 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pulmonx Corp - Total Liabilities Trend (2013–2025)
This chart illustrates how Pulmonx Corp's total liabilities have evolved over time, based on quarterly financial data. See LUNG net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Pulmonx Corp Competitors by Total Liabilities
The table below lists competitors of Pulmonx Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gapwaves AB Series B
ST:GAPW-B
|
Sweden | Skr46.48 Million |
|
MicroAlgo Inc.
NASDAQ:MLGO
|
USA | $15.58 Million |
|
SAMRYOONG Co.Ltd
KQ:014970
|
Korea | ₩41.95 Billion |
|
Green Cross Medical Science Corporation
KQ:142280
|
Korea | ₩44.56 Billion |
|
Sarveshwar Foods Limited
NSE:SARVESHWAR
|
India | Rs6.64 Billion |
|
OPAL Fuels Inc
NASDAQ:OPAL
|
USA | $433.95 Million |
|
Unick Corporation
KQ:011320
|
Korea | ₩177.94 Billion |
|
Sachem Capital Corp
NYSE MKT:SACH
|
USA | $285.11 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Pulmonx Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Pulmonx Corp.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pulmonx Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pulmonx Corp (2013–2025)
The table below shows the annual total liabilities of Pulmonx Corp from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $75.17 Million | -2.42% |
| 2024-12-31 | $77.04 Million | +29.55% |
| 2023-12-31 | $59.47 Million | +49.91% |
| 2022-12-31 | $39.67 Million | -5.40% |
| 2021-12-31 | $41.93 Million | +11.60% |
| 2020-12-31 | $37.57 Million | -84.40% |
| 2019-12-31 | $240.91 Million | +32.12% |
| 2018-12-31 | $182.34 Million | +11831.22% |
| 2017-12-31 | $1.53 Million | -55.23% |
| 2016-12-31 | $3.41 Million | -6.68% |
| 2015-12-31 | $3.66 Million | +93.73% |
| 2014-12-31 | $1.89 Million | +0.36% |
| 2013-12-31 | $1.88 Million | -- |
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ven… Read more